Kala Pharmaceuticals ( (KALA) ) has released its Q3 earnings. Here is a breakdown of the information Kala Pharmaceuticals presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kala Pharmaceuticals, now known as KALA BIO, Inc., is a biopharmaceutical company focused on developing treatments for rare and severe eye diseases. The company recently released its earnings report for the third quarter of 2025, highlighting significant financial and operational challenges. KALA BIO reported a net loss of $7.6 million for the quarter, with total assets decreasing to $25 million from $55.5 million at the end of 2024. The company also announced the cessation of its KPI-012 development program after failing to meet primary endpoints in a Phase 2b clinical trial, leading to a substantial workforce reduction. Despite these setbacks, KALA BIO is exploring strategic options, including potential asset sales or additional financing, to address its financial difficulties and continue its operations.